Home About Us Oncology Hematology Resources Clinical Trials Patient Forms Contact Us

Dr. Barreras > Publications

Research By Luis R. Barreras, M.D., FACP

Research experience as the principal investigator.

Research Experience

2011

Connect™ CLL Registry: The Chronic Lymphocytic Leukemia Disease Registry
Celgene

BI 1200.75 LUX BRT Trial: An open label, randomized Phase III Trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment.
Boehringer Ingelheim

CA225-346-030: A single arm multicenter Phase II safety study of Cisplatin and Vinorelbine in combination with Cetuximab as first line treatment for patient with advanced/metastatic NSCLC.
Bristol-Myers Squibb Company

2010

KLT-PANC-001: A randomized dose escalation, safety, and exploratory efficacy study of Kaglaite injection plus gemcitabine (G+K) versus gemcitabine in patients with advanced pancreatic cancer.
KangLaiTe, USA

OGX-011-10 “SATURN STUDY
”: A randomized, placebo-controlled, double blind, Phase III Study evaluating the clinical benefit of adding Custirsen to Docetaxel re-treatment/prednisone as an option for 2nd line therapy in men with castrate resistant prostate cancer Oncogenex Technologies, Inc.

Connect™ MM Registry
: An observational study designed to assess clinical and HRQoL outcomes in patients presenting with newly diagnosed MM [multiple myeloma] by comparing the effectiveness associated with common regimens
Celgene

FISCO Registry: A 5 year, prospective, non-interventional multicenter registry in sickle cell disease patients
Novartis

2009

EC-FV-04: A randomized Phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination, vs. PLD alone, in subjects with platinum-resistant ovarian cancer
Endocyte, Inc.

ACO11L08: A multi-center randomized Phase IIB study of Cetuximab (Erbitux®) in combination with platinum-based chemotherapy as first line treatment of patients with recurrent or advanced non-small cell lung cancer (NSCLC) Accelerated Community Oncology Research Network

2008

MORE Registry: A prospective, non-interventional multicenter registry in iron overloaded lower-risk myelodysplastic patients Novartis

AP23573-07-302: A pivotal trail to determine the efficacy and safety of AP23573 when administered as maintenance therapy to patients with metastatic soft-tissue or bone sarcomas ARIAD Pharmaceuticals

2007

EFC 6193 – TROPIC Study: A randomized, open label, multi-center study of XRP6258 at 25 mg/m2 in combination with prednisone every 3 wks compared to mitoxantrone in combination w/prednisone for the treatment of hormone refractory metastatic prostate cancer previously treated w/a Taxotere-containing regimen
Sanofi Aventis

AMP4074 – NSCLC: A randomized, double blind, Phase II trial of Paclitaxel + carboplatin + bevacizumab with or without APOMAB in patients with previously untreated, advanced stage NSCLC
Genentech

A6181087 – NSCLC: A multi-center, randomized, double-blind, controlled Phase III study of efficacy and safety study of sunitinib (SUO11248) in patients w/advanced metastatic NSCLC with erlotinib
Pfizer

A6101099 – BRT: A randomized, Phase III study of sunitinib in combination w/capecitabine compared with CAP in patients w/previously treated BRT cancer
Pfizer

DOSE REGISTRY: Anemia observational study of dosing and outcomes of erythropoiesis stimulating therapies
Ortho Biotech

PGT 307 – LUNG IN WOMEN ONLY: Paclitaxel poliglumex (CT-2103)/Carboplatin vs. Paclitaxel/carboplatin for the treatment of chemotherapy-naïve advanced non-small cell lung cancer (NSCLC) in women with estradiol 30pg/mL
CTI

PIX 203 – RAPID TRIAL: Phase II, Randomized, Multicenter, Comparative Trial of cyclophosphamide, doxorubicin, Vincristine, prednisone, + ritiximab (CHOP-R) and cyclophosphamide, pixantrone, Vincristine, prednisone + ritiximab (CPOP-R) in Patients w/Diffuse Large B-cell Lymphoma
CTI

EGF 104383: A Randomized, Double blind, Placebo-controlled, Multicenter, Phase III Study Comparing Activity of Paclitaxel + trastuzumab + lapatinib to Paclitaxel + trastuzumab + placebo in Women w/ErbB2 Overexpressing Metastatic BRT cancer
Glaxo Smith Kline

2006

NOVARTIS OPTIMIZE 2: A prospective, randomized, double-blinded, stratified, placebo-controlled, multi-center, 3-arm trial of the continued efficacy and safety of Zometa (every 4 wks vs. every 12 wks vs. placebo) in patients w/documented bone metastases from breast cancer
Novartis

UPCI 04-094: Phase III Trial of Adjuvant vs. Neo-adjuvant Chemotherapy w/cisplatin + Docetaxel for Patients w/early Stage NSCLC
University of Pittsburgh

CT-2103 (PIONEER) Study: Phase III Open Label Study of Paclitaxel poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Woman w/Chemo Naïve Advanced NSCLC who are PS 2
CTI

CPX-1: Phase II Chelator Study of CPX-1 (irinotecan Hcl: floxuridine) liposome Injection in Patients w/advanced Colorectal Cancer
Celator

Protocol 20050237
: A Prospective Observational Descriptive Study and Retrospective Chart Review of Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Amgen

BMS CA225009: A Randomized Multicenter Phase III Study of Taxane/Carboplatin/Cetuximab or Taxane/Carboplatin as First-Line Treatment for Patients with Advanced/Metastatic Non-Small Cell Lung Cancer
Bristol-Myer Squib

011-007: A Phase III, Randomized, Open-Label Study Evaluation DN-101 in Combination with Docetaxel in Androgen-Independent Prostrate Cancer (AIPC) (ASCENT-2)
Novacea

2005

TPU-S1301: An Open-Label, Multicenter, Randomized Phase III Study of S-1 in Combination with Cisplatin Compared against 5FU in Combination with Cisplatin in Patients with Advanced Gastric Cancer Previously Untreated with Chemotherapy for Advanced Disease
Taiho

DOXIL-BCA-3001: A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel for the Treatment of Advanced Breast Cancer
J&J PR&D

2004

PR03-27-063: A Double Blind Randomized Study to Evaluate the Response Rate of Procrit® (Epoetin Alfa) vs. Placebo in Anemic Patients with Cancer and Persistent Chemotherapy Induced Myelosuppression
Ortho Biotech

PR03-27-064: A Randomized Open-Label Study of Procrit® (Epoetin Alfa) at 60,000 Units or 80,000 Units Every Two Weeks in Anemic Patients with Cancer Receiving Chemotherapy
Ortho Biotech

Lung1Pilot
: Pilot Study of Lung Function and Chemotherapeutic Treatment of NSCLC and Preliminary Validation of Lung Cancer Survey Including a Global Patient Self-Reported Lung Symptom Question
Astra Zeneca (Quantros, Inc)

XRP9881B-3001: Phase III Study of XRP9881 vs. capecitabine (Xeloda®) in Patients with Metastatic BRT Cancer After Failure of Taxanes
Aventis

CA225014 (EXPLORE)
: Phase III Study of Cetuximab, Oxaliplatin, 5FU and LCV vs. Oxaliplatin, 5FU and LCV in Patient with Previously Treated Metastatic, EGFR-positive Colorectal Carcinoma
Bristol Myers Squibb

TLK286.3020: Phase III Study of TLK286 vs. gefitinib (Iressa®) as Third-Line Therapy in Locally Advanced or Metastatic NSCLC
Telik, Inc.

2003

PR03-27-007An Open-Label Pilot Study to Evaluate the Effects of Alternate Dosing of Procrit® (Epoetin Alfa) in the Treatment of Patients with Cancer and Chemotherapy Induced Anemia
Ortho Biotech

2002

ANC Study Group Registry: A Prospective Study of Neutropenic Complications Awareness of Neutropenia in Chemotherapy Study Group Albany Medical Center-Dr. Gary Lyman

2001

001-015 Phase II Study of SGN-15 (cBR96-Doxorubicin Immunoconjugate) Combined with Taxotere® in Patients with Hormone Refractory Prostate Cancer
Seattle Genetics

H2251n Phase IV Community-based study for clinical outcomes in patients with HER2 gene-amplified metastatic BRT cancer treated with 1st line Herceptin® in combination with a taxane
Genentech

PR 00-27-012 Phase IV Open Label Study of PROCRIT
(Epoetin alfa) in Women Undergoing Adjuvant Chemotherapy for Stage I, II, or III Breast Cancer
Ortho Biotech

SEQol-Study of ELLENCE* Quality of Life Phase III Randomized Study
of epirubicin/cyclophosphamide followed by taxane (sequential chemotherapy) vs epirubicin/taxane (concurrent chemotherapy) as adjuvant treatment for operable, node positive breast cancer
Pharmacia

2000

AG 3340-030 Phase IIII Compassionate Use Access to the Matrix
Agouron Pharmaceuticals

An Open-Label Study of a New Hematin Product-M00-246
Abbott Laboratories

NAFTA Trial - Phase III Study of Tamoxifen vs Toremifene
Roberts Pharmaceutical
(University of Louisville under grant from Orion Corp.)

M66104C - Phase IIIB Study Metastatic Breast Cancer
Xeloda and Taxol as 1st or 2nd line therapy
Roche

1999

VIN 40018 -Phase IV Study (NSCLC)
Glaxo Wellcome

The ILIAD Trial - Metastatic Renal Cell Carcinoma
Chiron Corporation

1998

Procrit Study
Ortho Biotech

AG 3340 MMP Phase II Study (LUNG & PROSTATE)
Agouron Pharmaceuticals

1997

PI for RTOG Protocol
Broward General Medical Center

Oral Ondansetron Study
Randomized Dose Comparison
Glaxo Wellcome
(Published 1999)

Daunoxome, Phase II Study
(BRT & NHL)
NeXstar

1996

Topotecan, Open Label Study
Smith Kline Beecham

Taxotere, Phase III Study
Rhone-Poulenc Rorer

Gemcitabine, IND Treatment Protocol
Lilly

Oxycontin, Phase III Analgesic Study
Purdue Frederick
Itasetron vs. Ondansetron, Phase III Study
Boehringer

1995

Alopecia, Phase II Study
University of Miami


Procrit, Phase III Anemia Related Study
Ortho Biotech
Navelbine, IND Study
Burroughs Wellcome

1990

CCOP & Comprehensive Cancer Research Group, Inc.

 

< Dr Barreras